What is DSGN (DSGN) stock price today?

DSGN (DSGN) is currently trading at $13.57, up 2.8% today.

What is DSGN P/E ratio?

DSGN's P/E ratio is -11.56. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is DSGN return on equity (ROE)?

DSGN's return on equity (ROE) is -32.86%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is DSGN's market cap?

DSGN has a market capitalization of $847.54M.

NMS · Biotechnology

DSGN (DSGN) Stock

$13.57 +2.80% NMS: DSGN Healthcare

Valuation

Metric	Value
Price	$13.57
Market Cap	$847.54M
P/E Ratio	-11.56
P/B Ratio	3.70
P/S Ratio	0.00
EPS (TTM)	$-1.22
52-Week High	$17.25
52-Week Low	$3.33
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-32.86%
ROA	-30.97%
ROCE	-37.26%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.01
Current Ratio	17.23

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-36.0M	$-68.0M	$-78.0M	$-62.0M	$-79.0M
Net Profit	$-36.0M	$-63.0M	$-67.0M	$-50.0M	$-70.0M
EPS	$-0.77	$-1.14	$-1.19	$-0.88	$-1.22
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$391.0M	$341.0M	$290.0M	$252.0M	$226.0M
Total Liabilities	$8.0M	$14.0M	$12.0M	$10.0M	$14.0M
Cash	$299.0M	$27.0M	$21.0M	$23.0M	$17.0M
Borrowings	$4.0M	$4.0M	$3.0M	$2.0M	$1.0M

Latest News

Fuchs Endothelial Corneal Dystrophy Market Forecast Highlights Significant Growth During the Forecast Period (2026-2036), Owing to the Expanding Treatment Landscape and Increasing Patient Pool | DelveInsight PR Newswire · Jul 6, 2026 Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1 GlobeNewswire · Jun 30, 2026 Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? Zacks · Jun 9, 2026 Protego Biopharma Appoints Jae B. Kim, MD, as Chief Medical Officer PR Newswire · Jun 8, 2026 Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference GlobeNewswire · May 28, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-29.0M	$-51.0M	$-59.0M	$-43.0M	$-54.0M
Investing Cash Flow	$-55.0M	$-222.0M	$52.0M	$44.0M	$23.0M
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$296.0M	$-272.0M	$-5.0M	$1.0M	$-6.0M
Free Cash Flow	$-31.0M	$-52.0M	$-59.0M	$-43.0M	$-55.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-8.10%
Quick Ratio	22.28
Interest Coverage	—
Return 1Y	172.37%
Return 3Y	62.66%
Return 5Y	-23.55%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALT	$3.03	-1.30%	-2.31	$267.42M	0.00%
ANNX	$5.37	+0.75%	-3.71	$879.83M	0.00%
AURA	$7.06	-1.40%	-4.35	$453.25M	0.00%
DMAC	$6.65	-1.27%	-8.09	$358.56M	0.00%
ENGN	$1.79	+1.70%	-0.70	$91.64M	0.00%

About DSGN

DSGN is led by CEO Pratik Shah, employs 56 people, headquartered in US, publicly traded since 2021.

DSGN stock trades at $13.57 with a market capitalization of $847.54M. The stock is valued at a price-to-earnings (P/E) ratio of -11.56, price-to-book of 3.70, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.33 and $17.25, and currently trades 21.3% below its 52-week high.

On profitability, DSGN generates a return on equity (ROE) of -32.86%, return on capital employed of -37.26%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides